Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer

The overexpression of wild type p73 is the most frequent alteration of p73 in malignancies. We investigated, in 70 breast carcinomas, p73 mRNA expression and its relationship to p53 mutations, determined by an immunohistochemical method, and loss heterozygosity (LOH) status of the 1p36 region, together with its possible implication in the pathogenesis of breast carcinomas. LOH, amplifying DNA by PCR using 5 markers, of 1p36 region (one intragenic to p73 gene) was found in 17% of cases but no significant correlation was observed with p73 overexpression. p53 positive immunostaining was present in 33% of breast carcinomas, and these exhibited a statistically significant relation with p73 overexpressed tumors. Overexpression of p73 mRNA was observed in 19 tumors (27%). The analysis of cases with p73 overexpression and cases with normal mRNA expression, in terms of age and pathologic characteristics of the tumors showed a significant association of p73 overexpression and tumors with lymph node metastases, vascular invasion and higher pathologic stage. These results suggest that p73 overexpression is a molecular alteration that could be implicated in the tumorigenesis of breast carcinomas and, eventually, in a poor clinical behavior.

[1]  L. Holmberg,et al.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.

[2]  A. Nakagawara,et al.  Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. , 1998, International journal of oncology.

[3]  Å. Borg,et al.  Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. , 1992, Genes, chromosomes & cancer.

[4]  F. Haluska,et al.  Mutational and expression analysis of the p73 gene in melanoma cell lines. , 1999, Cancer research.

[5]  Audenino Rg.  [Malignant tumors of the breast]. , 1960, El Dia medico.

[6]  D. Tindall,et al.  Activation of p73 silent allele in lung cancer. , 1998, Cancer research.

[7]  I. Bièche,et al.  Two distinct regions involved in 1p deletion in human primary breast cancer. , 1993, Cancer research.

[8]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[9]  F. Vikhanskaya,et al.  p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. , 2000, Nucleic acids research.

[10]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[11]  M. Genuardi,et al.  Distal deletion of chromosome Ip in ductal carcinoma of the breast. , 1989, American journal of human genetics.

[12]  W. Stolz,et al.  Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas , 1998, Melanoma research.

[13]  T. Zacharewski,et al.  pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers , 1999, Breast Cancer Research and Treatment.

[14]  S. Nomoto,et al.  Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. , 1998, Cancer research.

[15]  U. Moll,et al.  Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. , 1999, Cancer research.

[16]  G. Yang,et al.  Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. , 2000, Carcinogenesis.

[17]  S. Chi,et al.  Advances in Brief Elevated and Biallelic Expression of p 73 Is Associated with Progression of Human Bladder Cancer , 1999 .

[18]  Carl W. Miller,et al.  NEOPLASIA Loss of p 73 Gene Expression in Leukemias / Lymphomas Due to Hypermethylation , 1999 .

[19]  F. McKeon,et al.  p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent , 1999, Oncogene.

[20]  A. Nakagawara,et al.  Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. , 1998, Cancer Research.

[21]  Å. Borg,et al.  Chromosome I alterations in breast cancer: Allelic loss on Ip and Iq Is related to lymphogenic metastases and poor prognosis , 1992 .

[22]  S. Swendeman,et al.  Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[23]  C. Croce,et al.  Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. , 1995, Cancer research.

[24]  大藤 道衛.  Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus , 1995 .

[25]  J. Herman,et al.  Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. , 1999, Cancer research.

[26]  M. P. Neal.  MALIGNANT TUMORS OF THE MALE BREAST , 1933 .

[27]  Yohko Nakamura,et al.  Mutational analysis of the p73 Gene in human breast cancers , 1999, International journal of cancer.

[28]  C. Prives,et al.  p 53 Mutants in Mammalian Cells p 73 Function Is Inhibited by Tumor-Derived , 1999 .

[29]  David I. Smith,et al.  p73 mutations are not detected in sporadic and hereditary breast cancer , 1999, Breast Cancer Research and Treatment.

[30]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[31]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[32]  D. Housman,et al.  Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Byers,et al.  Cadherin-11 is expressed in invasive breast cancer cell lines. , 1999, Cancer research.

[34]  J. Pipas,et al.  Adenovirus E4orf6 oncoprotein modulates the function of the p53-related protein, p73. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Sakurada,et al.  Infrequent somatic mutations of the p73 gene in various human cancers. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[36]  N. Nomura,et al.  p73, a geme related to p53, is not mutated in esophageal carcinomas , 1998, International journal of cancer.

[37]  K. Engeland,et al.  Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. , 1999, Journal of the National Cancer Institute.

[38]  M. Broggini,et al.  Allelic expression of p73 in human ovarian cancers. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  B. Leggett,et al.  p73 Is up‐regulated in a subset of hepatocellular carcinomas , 2000, Hepatology.

[40]  Xinbin Chen,et al.  The potential tumor suppressor p73 differentially regulates cellular p53 target genes. , 1998, Cancer research.

[41]  W. Kaelin,et al.  Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73 , 1998, Molecular and Cellular Biology.